Novartis signed a heart medicine licensing agreement up to 5.2 billion dollars with China’s slang

China -based Biotech said in a statement on Wednesday that Swiss drug producer Novartis signed an agreement with licensing up to $ 5.2 billion and for experimental cardiovascular remedies with slang Biopharmautical.

The agreement includes an experimental genetic drug and two drug candidates in mid -stage study to control high blood fat levels and contains the option of licensing for some blood cholesterols that increase the risk of heart disease.

Slang, agreements are for sales outside China, he said.
Biotechnology, which develops genetic drugs, said that Novartis expresses a non -binding intention to participate in the next Self -Final Finance Tour.